1. 方法論と範囲
1.1. 調査方法
1.2. 調査目的と調査範囲
2. 定義と概要
3. エグゼクティブ・サマリー
3.1. 疾患タイプ別スニペット
3.2. 治療タイプ別スニペット
3.3. エンドユーザー別スニペット
4. ダイナミクス
4.1. 影響要因
4.1.1. 推進要因
4.1.1.1. 肝疾患の有病率の増加
4.1.2. 阻害要因
4.1.2.1. 治療に伴う高コスト
4.1.2.2. 厳しい規制要件
4.1.3. 機会
4.1.4. 影響分析
5. 産業分析
5.1. ポーターのファイブフォース分析
5.2. サプライチェーン分析
5.3. 価格分析
5.4. 規制分析
5.5. アンメット・ニーズ
5.6. PESTEL分析
5.7. 特許分析
5.8. SWOT分析
6. 疾患タイプ別
6.1. はじめに
6.1.1. 市場規模分析および前年比成長率分析（%）、疾患タイプ別
6.1.2. 市場魅力度指数、疾患タイプ別
6.2. 肝炎
6.2.1. 序論
6.2.2. 市場規模分析と前年比成長率分析(%)
6.3. 自己免疫疾患
6.4. 非アルコール性脂肪性肝疾患
6.5. 肝癌
6.6. 遺伝性疾患
6.7. その他
7. 治療タイプ別
7.1. はじめに
7.1.1. 治療タイプ別市場規模分析および前年比成長率分析（%） 7.1.2.
7.1.2. 市場魅力度指数（治療タイプ別
7.2. 抗ウイルス薬
7.2.1. 序論
7.2.2. 市場規模分析と前年比成長率分析(%)
7.3. 免疫抑制剤
7.4. ワクチン
7.5. 免疫グロブリン
7.6. 副腎皮質ステロイド
7.7. 標的療法
7.8. 化学療法薬
8. エンドユーザー別
8.1. はじめに
8.1.1. 市場規模分析および前年比成長率分析(%), エンドユーザー別
8.1.2. 市場魅力度指数、エンドユーザー別
8.2. 病院*市場
8.2.1. はじめに
8.2.2. 市場規模分析と前年比成長率分析(%)
8.3. 専門クリニック
8.4. 外来手術センター
8.5. その他
9. 競争環境
9.1. 競争シナリオ
9.2. 市場ポジショニング／シェア分析
9.3. M&A分析
10. 企業プロフィール
10.1. ファイザー *
10.1.1. 会社概要
10.1.2. 製品ポートフォリオと内容
10.1.3. 財務概要
10.1.4. 主な展開
10.2. サン・ファーマシューティカル・インダストリーズ社
10.3. ドクター・レディーズ・ラボラトリーズ・リミテッド
10.4. ザイダス・グループ
10.5. ルパン
10.6. マンカインド・ファーマ
10.7. トレント・ファーマシューティカルズ
10.8. アッヴィ社
10.9. ジョンソン・エンド・ジョンソンサービス
10.10. エフ・ホフマン・ラ・ロシュ・リミテッド (*リストは除く)
11. 付録
11.1. 会社概要とサービス
11.2. お問い合わせ
The Asia Pacific Liver disease treatment market reached US$ 3.84 billion in 2023 and is expected to reach US$ 5.83 billion by 2031, growing at a CAGR of 5.5% during the forecast period 2024-2031.
The liver disease treatment market is expanding rapidly, driven by the increasing prevalence of liver disorders such as hepatitis, fatty liver disease, and cirrhosis. Factors such as rising alcohol intake, obesity rates, and viral infections all contribute to this trend, creating a greater need for appropriate treatment solutions. The industry offers a wide range of medicines, including antiviral drugs, immunosuppressants, and new gene therapies.
Recent advances in biotechnology and pharmaceuticals have fueled innovation, with many corporations investing in research and development of new medications. This includes medications that target specific pathways involved in liver disease progression, which raises the prospect of more tailored and effective treatments. Furthermore, the growing focus on preventative interventions and early diagnosis is altering market
Dynamics, with healthcare providers increasingly.
Market Dynamics: Drivers
Increasing prevalence of liver diseases
The rising prevalence of liver diseases propels the market growth. For instance, according to the National Viral Hepatitis Control Program, anti-Hepatitis C virus antibody prevalence in the general population is estimated to be between 0.09 to 15%. Based on some regional-level studies, it is estimated that there are 6-12 million people with Hepatitis C in India.
Moreover, according to an article posted by Tropical Medicine and Health in August 2023, hepatitis is a major public health issue in Pakistan, with an estimated 11.55% prevalence of HCV infection in the adult population. The country ranks second globally in terms of hepatitis C virus (HCV) infections, with approximately one in every 20 Pakistanis already infected.
Moreover, according to the World Health Organization, it is estimated that Cambodia has a prevalence of hepatitis C between 2.0 and 2.9%. The prevalence of the hepatitis C (anti-HCV positive) ranged from 0.87 to 14.7%. In India, as per the latest estimates, 40 million people are chronically infected with hepatitis B and six to 12 million people are chronically infected with hepatitis C.
Restraints
Factors such as high costs associated with the treatment and stringent regulatory requirements for the approval of new treatments are expected to hamper the market. The higher costs of drugs that are associated with the treatment of various liver diseases affect the affordability for many people and this acts as a restraint to the Asia Pacific Liver disease treatment market.
Market Segment Analysis
The Asia Pacific liver disease treatment market is segmented based on disease type, treatment type, and end-user.
The segment non-alcoholic fatty liver disease accounted for approximately 42.8% of the Asia Pacific liver disease treatment market share.
The non-alcoholic fatty liver disease segment is expected to hold the largest market share over the forecast period. In this segment, the increasing prevalence and recent treatment approvals would drive this market.
Nonalcoholic fatty liver disease (NAFLD) is a condition in which excess fat builds up in your liver. This buildup of fat is not caused by heavy alcohol use. When heavy alcohol use causes fat to build up in the liver, this condition is called alcohol-associated liver disease. Two types of NAFLD are nonalcoholic fatty liver (NAFL) and nonalcoholic steatohepatitis (NASH). People typically develop one type of NAFLD or the other, although sometimes people with one form are later diagnosed with the other form of NAFLD.
For instance, according to the National Institute of Health, the prevalence of adult NAFLD in India has been reported between 6.7% and 55.1%. Of all cases with an asymptomatic elevation of liver enzymes, NAFLD may be responsible for almost one-third. Furthermore, explant histology data from liver transplant centers suggest that two-thirds of the patients with ‘cryptogenic’ cirrhosis had NAFLD. The prevalence of pediatric NAFLD in India varies from 7.3% to 22.4% in the healthy population. The prevalence of NAFLD increases with age.
Market Segmentation
By Disease Type
Hepatitis
Autoimmune Diseases
Non-Alcoholic Fatty Liver Disease
Liver Cancer
Genetic Disorder
Others
By Treatment Type
Antiviral Drugs
Sofosbuvir
Ombitasvir
Immunosuppressants
Vaccines
Hepatitis B vaccine
Hepatitis A vaccine
Combined hepatitis A and B vaccine
Immunoglobulins
Corticosteroids
Prednisone
Targeted Therapy
Sorafenib
Regorafenib
Chemotherapy Drugs
Nivolumab
Pembrolizumab
By End-User
Hospitals
Specialty Clinics
Ambulatory Surgical Centers
Others
Market Competitive Landscape
The major global players in the Asia Pacific liver disease treatment market include Pfizer Inc., Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd, Zydus Group, Lupin, Mankind Pharma, Torrent Pharmaceuticals Ltd., AbbVie Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd among others.
Key Developments
In February 2024, Immune-Onc Therapeutics entered into a clinical trial partnership with Roche for a Phase Ib/II clinical trial of IO-108 plus atezolizumab and bevacizumab to treat hepatocellular carcinoma (HCC), the most common type of liver cancer. IO-108 is a LILRB2-directed antibody of Immune-Onc while atezolizumab and bevacizumab are Roche’s cancer immunotherapy combination regimen.
Why Purchase the Report?
To visualize the Asia Pacific liver disease treatment
Market Segmentation based on disease type, treatment type, and end-user as well as understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development
Excel data sheet with numerous data points of Asia Pacific liver disease treatment market level with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping is available in Excel consisting of key products of all the major players.
The Asia Pacific liver disease treatment market report would provide approximately 51 tables, 54 figures, and 181 Pages.
Target Audience 2024
Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies
1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Disease Type
3.2. Snippet by Treatment Type
3.3. Snippet by End-User
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing Prevalence of Liver Diseases
4.1.2. Restraints
4.1.2.1. High Cost Associated with the Treatment
4.1.2.2. Stringent Regulatory Requirements
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Unmet Needs
5.6. PESTEL Analysis
5.7. Patent Analysis
5.8. SWOT Analysis
6. By Disease Type
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
6.1.2. Market Attractiveness Index, By Disease Type
6.2. Hepatitis *
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Autoimmune Diseases
6.4. Non-Alcoholic Fatty Liver Disease
6.5. Liver Cancer
6.6. Genetic Disorder
6.7. Others
7. By Treatment Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
7.1.2. Market Attractiveness Index, By Treatment Type
7.2. Antiviral Drugs *
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Immunosuppressants
7.4. Vaccines
7.5. Immunoglobulins
7.6. Corticosteroids
7.7. Targeted Therapy
7.8. Chemotherapy Drugs
8. By End-User
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
8.1.2. Market Attractiveness Index, By End-User
8.2. Hospitals*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Specialty Clinics
8.4. Ambulatory Surgical Centers
8.5. Others
9. Competitive Landscape
9.1. Competitive Scenario
9.2. Market Positioning/Share Analysis
9.3. Mergers and Acquisitions Analysis
10. Company Profiles
10.1. Pfizer Inc. *
10.1.1. Company Overview
10.1.2. Product Portfolio and Description
10.1.3. Financial Overview
10.1.4. Key Developments
10.2. Sun Pharmaceutical Industries Ltd.
10.3. Dr. Reddy’s Laboratories Ltd
10.4. Zydus Group
10.5. Lupin
10.6. Mankind Pharma
10.7. Torrent Pharmaceuticals Ltd.
10.8. AbbVie Inc.
10.9. Johnson & Johnson Services Inc.
10.10. F. Hoffmann-La Roche Ltd (*LIST NOT EXHAUSTIVE)
11. Appendix
11.1. About Us and Services
11.2. Contact Us
❖ 世界の肝疾患治療市場に関するよくある質問(FAQ) ❖
・肝疾患治療の世界市場規模は？
→DataM Intelligence社は2023年の肝疾患治療の世界市場規模を38.4億米ドルと推定しています。
・肝疾患治療の世界市場予測は？
→DataM Intelligence社は2031年の肝疾患治療の世界市場規模を58.3億米ドルと予測しています。
・肝疾患治療市場の成長率は？
→DataM Intelligence社は肝疾患治療の世界市場が2024年～2031年に年平均5.5%成長すると予測しています。
・世界の肝疾患治療市場における主要企業は？
→DataM Intelligence社は「Pfizer Inc., Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd, Zydus Group, Lupin, Mankind Pharma, Torrent Pharmaceuticals Ltd., AbbVie Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltdなど ...」をグローバル肝疾患治療市場の主要企業として認識しています。
※上記FAQの市場規模、市場予測、成長率、主要企業に関する情報は本レポートの概要を作成した時点での情報であり、納品レポートの情報と少し異なる場合があります。
